Cargando…

Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D

A high percentage of patients with chronic kidney disease have hypovitaminosis D, which is a driver of secondary hyperparathyroidism and an important factor in chronic kidney disease-mineral and bone disorder. Vitamin D deficiency (serum total 25-OH vitamin D levels < 30 ng/mL) occurs early in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cozzolino, Mario, Minghetti, Paola, Navarra, Pierluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995284/ https://www.ncbi.nlm.nih.gov/pubmed/34626363 http://dx.doi.org/10.1007/s40620-021-01152-5

Ejemplares similares

Hypovitaminosis D: Is It Time to Consider the Use of Calcifediol?
por: Cesareo, Roberto, et al.
Publicado: (2019)

Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism
por: Bishop, Charles W., et al.
Publicado: (2022)

Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis
por: Franchi, Matteo, et al.
Publicado: (2023)

Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
por: Germain, Michael J., et al.
Publicado: (2022)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Hypovitaminosis D in chronic kidney disease
por: Bucharles, Sérgio Gardano Elias, et al.
Publicado: (2021)

A Randomized, Open-Label Study to Assess Efficacy of Weekly Assumption of Cholecalciferol versus Calcifediol in Older Patients with Hypovitaminosis D
por: Okoye, Chukwuma, et al.
Publicado: (2022)

Hypovitaminosis D masking hypercalcemia in primary hyperparathyroidism: case report
por: Elsherbiny, Tamer Mohamed
Publicado: (2023)

LBSAT229 Extended-release Calcifediol Effectively Raised 25-hydroxyvitamin D In CKD Despite Obesity
por: Strugnell, Stephen A, et al.
Publicado: (2022)

LBSAT131 Extended-release Calcifediol Reduced Ipth And Normalized 1,25-dihydroxyvitamin D In Esrd.
por: Ashfaq, Akhtar, et al.
Publicado: (2022)

REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients
por: Bishop, Charles W., et al.
Publicado: (2023)

Calcifediol: Mechanisms of Action
por: Donati, Simone, et al.
Publicado: (2023)

Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis
por: Cozzolino, Mario, et al.
Publicado: (2021)

Effects of calcifediol supplementation on markers of chronic kidney disease‐mineral and bone disorder in dogs with chronic kidney disease
por: Parker, Valerie J., et al.
Publicado: (2020)

Cholecalciferol or Calcifediol in the Management of Vitamin D Deficiency
por: Sosa Henríquez, Manuel, et al.
Publicado: (2020)

Calcifediol Cornerstone of the Vitamin D Endocrine System
por: Quesada-Gomez, Jose Manuel, et al.
Publicado: (2023)

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
por: Cozzolino, Mario, et al.
Publicado: (2017)

Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice
por: Alfieri, Carlo, et al.
Publicado: (2019)

Effect of calcifediol supplementation on renin‐angiotensin‐aldosterone system mediators in dogs with chronic kidney disease
por: Miller, Matthew, et al.
Publicado: (2022)

Secondary hyperparathyroidism among Nigerians with chronic kidney disease
por: Gimba, Zumnan M, et al.
Publicado: (2018)

Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management
por: Habas, Elmukhtar, et al.
Publicado: (2021)

Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4
por: Dheerendra, P. C., et al.
Publicado: (2013)

Rapid Nontranscriptional Effects of Calcifediol and Calcitriol
por: Donati, Simone, et al.
Publicado: (2022)

Calcifediol for Use in Treatment of Respiratory Disease
por: Entrenas-Castillo, Marta, et al.
Publicado: (2022)

Calcifediol: Why, When, How Much?
por: Donati, Simone, et al.
Publicado: (2023)

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
por: Roggeri, Alessandro, et al.
Publicado: (2020)

Effectiveness of Native Vitamin D Therapy in Patients with Chronic Kidney Disease Stage 3 and Hypovitaminosis D in Colombia, South America
por: Restrepo-Valencia, Cesar A, et al.
Publicado: (2019)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease
por: Naveh-Many, Tally, et al.
Publicado: (2020)

Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
por: Friedl, Claudia, et al.
Publicado: (2017)

Hypovitaminosis
Publicado: (1943)

Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?
por: Pasquali, Marzia, et al.
Publicado: (2015)

25(OH)Vitamin D Deficiency and Calcifediol Treatment in Pediatrics
por: Castano, Luis, et al.
Publicado: (2022)

Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol
por: Quesada-Gomez, Jose Manuel, et al.
Publicado: (2022)

Association of Secondary Hyperparathyroidism with Hemoglobin Level in Patients with Chronic Kidney Disease
por: Chutia, Happy, et al.
Publicado: (2013)

Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease
por: Rodríguez-Ortiz, María E., et al.
Publicado: (2020)

Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective
por: Chandran, Manju, et al.
Publicado: (2019)

Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease
por: Xu, Yang, et al.
Publicado: (2021)

Complications after radiofrequency ablation of hyperparathyroidism secondary to chronic kidney disease
por: Lin, Li-Ping, et al.
Publicado: (2023)

Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment
por: Joy, Melanie S., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_fsat7o1fg5hqr3scq5dbn4k79i